Oddity, the parent company of Il Makiage, has launched a new brand called Methodiq, focusing on medical-grade skin care. Methodiq offers 28 products, ranging from $29 to $59, addressing acne, hyperpigmentation, and eczema. The brand combines biotechnology, AI-based imaging, and digital retailing to tap into the $113 billion medical skin care market.

Methodiq directly competes with Hims in offering telehealth platforms for skin care. Oddity plans to expand further into health care by leveraging its 60 million user platform. Although Methodiq is not included in revenue outlooks, the brand has significant revenue potential in the future, aiming to emulate Hims’ $6.5 billion annual revenue goal by 2030.

Oddity’s expansion into medical skin care introduces challenges such as regulatory scrutiny, increasing competition, and building customer trust. Telehealth platforms like Hims have faced criticism for not adequately disclosing side effects of their products. Methodiq aims to address these challenges by offering personalized skin care solutions and access to medical professionals.

Methodiq utilizes AI-based imaging from Voyage81 and new molecules from Oddity Labs to personalize skin care solutions for consumers. Patients receive customized kits with prescribed medications and innovative products like Clindalaq, a prescription-strength acne treatment with added ingredients for better tolerability and effectiveness. Methodiq aims to deliver a unique beauty experience in a prescription formula.

With over 50 million Americans affected by acne and 1 in 10 experiencing eczema, Methodiq aims to bridge the gap in dermatological care by providing access to medical professionals and effective products. The platform connects patients with clinicians, who review their intake, recommend products, and monitor progress. While not all doctors are dermatologists, the platform aims to increase access to care for common skin concerns.

Read more at CNBC: Oddity launches telehealth skincare platform Methodiq